Inventor · disambiguated record
Vernon D. Rowe
Also filed as: ROWE VERNON D · ROWE VERNON E
5 granted patents·5 pending applications·14 citations·filing 2001–2012
72Inventor score
Top patents by PatentIndex Score
10 records- 0171US6903100B2Use of regularly scheduled high dose intravenous methotrexate therapy, with interim administration of immunomodulatory agents, to treat multiple sclerosis and other diseases of the central nervous systemMIDAMERICA NEUROSCIENCE RES FO·Filed 2002·Granted Jun 7, 2005·11 cites·42 claims
- 0264US8192721B2Compositions useful for reducing toxicity associated with gadolinium-based contrast agentsROWE VERNON D·Filed 2008·Granted Jun 5, 2012·3 cites·12 claims
- 0363US8277779B2Compositions useful for reducing nephrotoxicity and methods of use thereofROWE VERNON D·Filed 2009·Granted Oct 2, 2012·0 cites·10 claims
- 0454US8574551B2Compositions useful for reducing nephrotoxicity and methods of use thereofROWE VERNON D·Filed 2012·Granted Nov 5, 2013·0 cites·13 claims
- 0553US7658913B2Compositions useful for reducing nephrotoxicity and methods of use thereofVERROW PHARMACEUTICALS INC·Filed 2007·Granted Feb 9, 2010·0 cites·2 claims
- 0643US2011027390A1Methods for Reducing Cisplatin NephrotoxicityVERROW PHARMACEUTICALS INC·Filed 2010·Application pending·0 cites
- 0743US2004048871A1Use of high dose intravenous methotrexate, with leucovorin rescue, to treat early multiple sclerosis and other diseases of the central nervous systemFiled 2002·Application pending·0 cites
- 0843US2011028413A1Methods of Reducing Methotrexate NephrotoxicityVERROW PHARMACEUTICALS INC·Filed 2010·Application pending·0 cites
- 0938US2007123478A1Compositions useful for reducing nephrotoxicity and methods of use thereofROWE VERNON D·Filed 2006·Application pending·0 cites
- 1035US2005066178A1Method and apparatus for controlling access to memoryFiled 2001·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Vernon D. Rowe files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →